novo nordisk - Search News

Novo Nordisk's next-gen obesity drug Cagrisema

CNBC on MSN · 32m

Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.

The New York Times · 3h

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Novo Nordisk's stock rises

The Motley Fool on MSN · 1h

Why Novo Nordisk Stock Is Soaring Today

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but gained as much as 5.8% earlier in the day. The leg up comes as the S&P 500 ( ^GSPC 0.26%) gained 0.2%, and the Nasdaq Composite ( ^IXIC 0.02%) lost 0.1% on the day.

Indiatimes on MSN · 26m

Novo Nordisk's stock rises as Ozempic beat analysts' expectations in sales

In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage notifications'.

MarketWatch on MSN · 11h

Novo Nordisk sales beat estimates, but the story wasn’t Ozempic

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs.

5h

Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

1h

Novo Nordisk 'comfortable' with impact of Medicare price negotiations for GLP-1s: CEO

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

6h

Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

9h

Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

4hon MSN

Novo Nordisk defends next-gen obesity drug CagriSema, details new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results